A phase I study of Rad-001 [everolimus] and sunitinib in metastatic renal cell carcinoma patients.

Trial Profile

A phase I study of Rad-001 [everolimus] and sunitinib in metastatic renal cell carcinoma patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2010

At a glance

  • Drugs Everolimus; Sunitinib
  • Indications Renal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2010 Actual end date (Feb 2010) and actual number of patients (20) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top